Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an author produced version of a paper subsequently published in Annals of Oncology. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | renal cell carcinoma; tyrosine kinase inhibitor; biomarker; SRC; VEGF |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 13 Jul 2016 15:47 |
Last Modified: | 14 Apr 2017 02:51 |
Published Version: | http://dx.doi.org/10.1093/annonc/mdw014 |
Status: | Published |
Publisher: | Oxford University Press |
Refereed: | Yes |
Identification Number: | 10.1093/annonc/mdw014 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:101660 |